Literature DB >> 15863372

Who will benefit from treatment against EGFR?

Joaquín Arribas, José Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15863372     DOI： 10.1016/S1470-2045(05)70142-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Cell signalling: growth factors and tyrosine kinase receptors.

Authors:  Rosario Perona
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

2.  Antibody-based targeted therapy for gastric cancer.

Authors:  Florian Lordick; Christian Peschel; Jörg Rüdiger Siewert
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 3.  Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer.

Authors:  Jose A García-Sáenz; Javier Sastre; Eduardo Díaz-Rubio García
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

4.  Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

Authors:  Wenjing Yang; Yibo Gao; Xuelian Li; Jing Zhang; Tiejun Liu; Xiaoli Feng; Hao Pan; Xiaofan Yang; Shuanghua Xie; Xiaoshuang Feng; Zhangyan Lv; Yonggang Wang; Zhaoli Chen; Jie He
Journal:  World J Surg Oncol       Date:  2017-11-06       Impact factor: 2.754
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.